RDIF and Stelis Biopharma collaborate to supply 200 million doses of Sputnik V vaccine

Russian Direct Investment Fund (RDIF) and the biopharmaceutical division of Strides Pharma Ltd namely, Stelis Biopharma Pvt Ltd have partnered together to produce & supply a minimum of 200 million doses of Russian COVID-19 vaccine, Sputnik V.  

The agreement between RDIF and Stelis Biopharma was reached under the aegis of Enso Healthcare LLP, RDIF's coordination partner for sourcing Sputnik V vaccines in India. The doses will be sufficient enough to inoculate 100 million people.   

Sputnik V is the world’s first registered vaccine against the novel Coronavirus infection. It has now been approved for use by more than 50 countries. The vaccine demonstrates a healthy efficacy rate of 91.6 per cent and it was found consistent & protective across all participant age groups. The supply of the vaccines may begin from the third quarter of 2021.  

At 3.21 pm on Friday, the stock of Strides Pharma Science Ltd was down by 1.11 per cent, trading at a price of Rs 764.65.  

---